drugset
drugset / Trial / NCT02259894

Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX in Healthy Male Volunteers

NCT02259894 ↗

Phase 1 Completed 55 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess safety, tolerability, pharmacokinetics, and pharmacodynamics of BIRT 2584 XX in single rising oral doses of 5 mg to 700 mg in a polyethylene glycol 400 (PEG 400) solution in healthy subjects

Timeline

Start
2004-03
Primary completion
2004-06
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BIRT 2584 XX Unknown 5 mg Oral
Subject BIRT 2584 XX Unknown 30 mg Oral
Subject BIRT 2584 XX Unknown 100 mg Oral
Subject BIRT 2584 XX Unknown 200 mg Oral
Subject BIRT 2584 XX Unknown 350 mg Oral
Subject BIRT 2584 XX Unknown 500 mg Oral
Subject BIRT 2584 XX Unknown 700 mg Oral

Indications

No indication recorded.